ROMANCE: "Irinotecan Plus Cetuximab Rechallenge Versus Trifluridine/Tipiracil Plus Bevacizumab in Molecularly Selected Metastatic Colorectal Cancer"

This study is a phase II, open-label, multicenter clinical trial designed to evaluate two different treatment options for patients with metastatic colorectal cancer whose disease has progressed after standard therapies. The study compares a rechallenge treatment using irinotecan plus cetuximab with the current standard of care, trifluridine/tipiracil plus bevacizumab, as third-line therapy. Patients enrolled in the study are selected based on specific molecular characteristics of their cancer, identified through circulating tumor DNA analysis from a blood sample. The main purpose of the study

Trial Details

NCT ID
NCT07381764
Phase
PHASE2
Sponsor
Gruppo Oncologico Italia Meridionale
Status
RECRUITING
Cancer Type
Colorectal Cancer
Interventions
  • Erbitux (Cetuximab)
  • Bevacizumab
  • Irinotecan
  • Trifluridine/tipiracil
Locations (sample)
  • Alessandria, Italy|44.90924,8.61007
  • Ancona, Italy|43.60717,13.5103
  • Aviano, Italy|46.07056,12.59472
  • Caserta, Italy|41.07262,14.33231
  • Castellana Grotte, Italy|40.88643,17.16549

Key Eligibility Criteria

  • Male or female aged ≥18 years
  • Eastern Cooperative Oncology Group Performance Status (ECOG-PS) ≤1
  • Diagnosis of histologically or cytologically confirmed colorectal cancer.
  • At least one measurable lesion according to RECIST1.1

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →